Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

napsr Press Releases

  + XML/RSS  



By NAPSRx
GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

By NAPSRx
The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

By NAPSRx
Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

By NAPSRx
Avastin becomes the first biologic medicine to approved in combination with chemotherapy to help women with advanced cervical cancer live longer.

By NAPSRx
Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

By NAPSRx
The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

By NAPSRx
Actavis plc (NYSE: ACT) is a specialty pharmaceutical company specializing in developing, manufacturing and commercializing generic drugs and branded pharmaceutical products.

By NAPSRx
Teva is a manufacturer of generics and specialty pharmaceuticals and is currently the world leader in generic drug sales.

By NAPSRx
The approval of Stiverdi Respimat is another great achievement for Boehringer Ingelheim as they continuously expand on their respiratory product pipeline.

By NAPSRx
AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

By NAPSRx
Bayer Group had an impressive second quarter for 2014 as earnings climbed based on successful drug launches and the company's established product pipeline.

By NAPSRx
IMBRUVICA®, a jointly developed therapy from Pharmacyclics, Inc. and Janssen Biotech received full Approval based on Phase 3 RESONATE™ study data

By NAPSRx
Abbvie is a global biopharmaceutical specializing in the discovery and advancement of innovative therapies to meet the health needs of people and societies around the globe.

By NAPSRx
Based on industry analysis, the emerging healthcare market will experience a continuous growth in the pharmaceutical sales sector.

By NAPSRx
Cubist Pharmaceuticals, Inc announced on Friday, June 20, 2014 that the U.S. Food and Drug Administration (FDA) approved Sivextro to treat bacterial skin infections.

By NAPSR
Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts.

By NAPSR
According to the Centers for Disease Control, more than two million people come down with antibiotic-resistant infections annually, and at least 23,000 die because their treatment can't stop the infection. In addition, the pipeline for new antibiotic

By NAPSR
Artificial bone marrow may be used to reproduce hematopoietic stem cells. A prototype has now been developed by scientists of KIT, the Max Planck Institute for Intelligent Systems, Stuttgart, and Tübingen University (Germany).

By NAPSR
Pfizer Inc. reported financial results for third-quarter 2013. Reported revenues decreased $310 million, or 2%, which reflects an operational decline of $38 million, or less than 1%, and the unfavorable impact of foreign exchange of $272 m

By NAPSR
University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's disease genetics collaboration, which identified 11 new regions of the genome that contribute to late-onset Alzheimer's disease.

All Press Releases

By NAPSRx
GlaxoSmithKline (GSK)– a world leader in the healthcare industry specializes in researching and developing vaccines, medicines and consumer healthcare products to improve people’s health and well-being.

By NAPSRx
Cerdelga™ is the only first-line oral therapy approved to treat adults with Type 1 Gaucher Disease, a rare genetic disorder that affects specific cells and organs in the body.

By NAPSRx
The investigational antibiotic CAZ-AVI was studied in patients with intra-abdominal infections (cIAI).

By NAPSRx
Based on favorable results obtained from the ADVANCE Phase 3 Study, the FDA approval of PLEGRIDY™ signifies a blockbuster therapeutic achievement for Biogen Idec .

By NAPSRx
Avastin becomes the first biologic medicine to approved in combination with chemotherapy to help women with advanced cervical cancer live longer.

By NAPSRx
Industry leader Sanofi and MannKind Corp have agreed to a enter into a global licensing agreement to develop and market AFREZZA® (Insulin human) rapid- acting inhaled insulin.

By NAPSRx
The collaboration between Daiichi Sankyo and Charleston Labs marks a significant venture for the pain management market.

By NAPSRx
Actavis plc (NYSE: ACT) is a specialty pharmaceutical company specializing in developing, manufacturing and commercializing generic drugs and branded pharmaceutical products.

By NAPSRx
Teva is a manufacturer of generics and specialty pharmaceuticals and is currently the world leader in generic drug sales.

By NAPSRx
The approval of Stiverdi Respimat is another great achievement for Boehringer Ingelheim as they continuously expand on their respiratory product pipeline.

By NAPSRx
AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.

By NAPSRx
Bayer Group had an impressive second quarter for 2014 as earnings climbed based on successful drug launches and the company's established product pipeline.

By NAPSRx
IMBRUVICA®, a jointly developed therapy from Pharmacyclics, Inc. and Janssen Biotech received full Approval based on Phase 3 RESONATE™ study data

By NAPSRx
Abbvie is a global biopharmaceutical specializing in the discovery and advancement of innovative therapies to meet the health needs of people and societies around the globe.

By NAPSRx
Based on industry analysis, the emerging healthcare market will experience a continuous growth in the pharmaceutical sales sector.

By NAPSRx
Cubist Pharmaceuticals, Inc announced on Friday, June 20, 2014 that the U.S. Food and Drug Administration (FDA) approved Sivextro to treat bacterial skin infections.

By NAPSR
Researchers at the University of Illinois at Chicago have developed a system for precisely delivering anti-inflammatory drugs to immune cells gone out of control, while sparing their well-behaved counterparts.

By NAPSR
According to the Centers for Disease Control, more than two million people come down with antibiotic-resistant infections annually, and at least 23,000 die because their treatment can't stop the infection. In addition, the pipeline for new antibiotic

By NAPSR
Artificial bone marrow may be used to reproduce hematopoietic stem cells. A prototype has now been developed by scientists of KIT, the Max Planck Institute for Intelligent Systems, Stuttgart, and Tübingen University (Germany).

By NAPSR
Pfizer Inc. has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK's trametinib combined with Pfizer's palbociclib (PD-0332991) in a Phase I/II study in patients with advanced/metastatic melanoma.

By NAPSR
A study published in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure.

By NAPSRx
The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team has identified a family of enzymes.

By NAPSR
The Bayer Group continued its positive business momentum in the third quarter of 2013, with substantial contributions from the Life Science businesses HealthCare and CropScience

By NAPSR
A team of 22 scientists from 11 research institutes led by Professor Bazbek Davletov, now at the University of Sheffield, created and characterised a new molecule that was able to alleviate hypersensitivity to inflammatory pain.

By NAPSR
Pfizer Inc. reported financial results for third-quarter 2013. Reported revenues decreased $310 million, or 2%, which reflects an operational decline of $38 million, or less than 1%, and the unfavorable impact of foreign exchange of $272 m

By NAPSR
An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C)

By NAPSR
A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established.

By NAPSR
University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's disease genetics collaboration, which identified 11 new regions of the genome that contribute to late-onset Alzheimer's disease.

By NAPSR
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel.

By NAPSR
In a feat of modern-day alchemy with huge potential for regenerative medicine, Stanford University School of Medicine scientists have developed a fast, efficient way to turn cells extracted from routine liposuction into liver cells.

By NAPSR
Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits, one of them helped by a big government purchase.

By NAPSR
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.

By NAPSR
Parvoviruses cause no harm in humans, but they can kill cancer cells. Scientists at the German Cancer Research Center have been studying these viruses with the aim of developing a viral therapy to treat a type of aggressively growing brain cancer.

By NAPSR
Scientists have combined cutting edge computer modelling with pharmacology and medicinal chemistry to reveal new insights into how the body interacts with novel drug treatments.

By NAPSR
Abbott today announced financial results for the third quarter ended Sept. 30, 2013. Third-quarter 2013 worldwide sales of $5.4 billion increased 4.3 percent on an operational basis, with strong performance in Diagnostics and Medical Devices.

By NAPSR
A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment.

By NAPSR
Early treatment of heart attack patients with an inexpensive beta-blocker drug called metoprolol, can significantly reduce damage to the heart during a myocardial infarction.

By NAPSR
A group of Brigham and Women's Hospital, and Harvard Stem Cell Institute researchers, and collaborators at MIT and Massachusetts General Hospital have found a way to use stem cells as drug delivery vehicles.

By NAPSR
A global hunt for genes that influence heart disease risk has uncovered 157 changes in human DNA that alter the levels of cholesterol and other blood fats - a discovery that could lead to new medications.

By NAPSR
The International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) have announced their collaboration on a new grant opportunity focused on improving care for patients around the world with cardiovascular risk.

By NAPSR
Researchers from Université Laval's Faculty of Medicine and CHU de Québec have shown that it is possible to treat venous ulcers unresponsive to conventional treatment with wound dressings made from human skin grown in vitro

By NAPSR
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC).

By NAPSR
Olivier Brandicourt (57) has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013.

By NAPSR
Bayer HealthCare today announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development has granted two separate orphan drug designations for its investigational, oral medication riociguat

By NAPSR
Viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.

By NAPSR
Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis is released.

By NAPSR
At the forthcoming Annual Shareholders Meeting on 4 March 2014, the Roche Board of Directors will propose Christoph Franz to be elected as Chairman of the Board.

By NAPSR
The Bayer Cares Foundation and Caritas Argentina have laid the foundation for a new project to combat the Chagas disease in Argentina.

By NAPSR
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed an innovative drug-delivery system in which tiny particles called nanodiamonds are used to carry chemotherapy drugs directly into brain tumors

By NAPSR
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg and Regensburg University, both in Germany, and the University of Lisboa, in Portugal, have discovered a promising potential drug target for cystic fibrosis.



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share